BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/41189

A. CLAS IPC(7)	SSIFICATION OF SUBJECT MATTER : C12Q 1/68; A01N 43/04; C07H 21/04; A61K	31/07							
US CL: 435/6, 325, 375, 91.1; 536/23.1, 24.5, 24.3; 514/44; 424/134.1 According to International Patent Classification (IPC) or to both national classification and IPC									
		national class	sification and IPC						
B. FTELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols)									
	cumentation searched (classification system followed 35/6, 325, 375, 91.1; 536/23.1, 24.5, 24.3; 514/44;		ation symbols)						
Documentati	on searched other than minimum documentation to the	e extent that	such documents are included	d in the fields searched					
	ta base consulted during the international search (national source) ontinuation Sheet	me of data ba	ase and, where practicable, s	earch terms used)					
	UMENTS CONSIDERED TO BE RELEVANT								
Category *	Citation of document, with indication, where a			Relevant to claim No.					
X	CHAN et al. Human BUBR1 is a mitotic checkpoi functions at kinetochores and binds the cyclosome/. September 1999, Vol. 146, Number 5, pages 941-9	1, 7, 8, 9, 11-15, 21, 22, 23, 25, 26-32, 38, 39, 40, 42, 43, 44, 45, 47-50, 52, 53, and 54							
X	GORBSKY et al. Microinjection of antibody to Mamitosis induceds premature anapha.se. Journal of C Number 5, pages 1193-1205, see Figures 1-11.	1, 8, 10, 13, 15, 21, 22, 24, 27, 29, 30, 31, 32, 38, 39, 41, 44, 47, 48, 49, 51, and 54							
X,E	US 2004/0101856 A1 (BENNETT et al.) 27 May [0038], page 8 [0065] and [0066].	2004 (27.05.	2004), see page 5, [0037],	1,2,4,15,16,1832, 33,35,46,51, and 54					
	·			·					
Further	documents are listed in the continuation of Box C.		See patent family annex.						
* S	pecial categories of cited documents:		later document published after the inte						
	defining the general state of the art which is not considered to be lar relevance	:	date and not in conflict with the applic principle or theory underlying the inve	ention					
•	plication or patent published on or after the international filing date		document of particular relevance; the considered novel or cannot be conside when the document is taken alone						
	which may throw doubts on priority claim(a) or which is cited to the publication date of another citation or other special reason (as		document of particular relevance; the considered to involve an inventive step combined with one or more other such	when the document is					
"O" document	referring to an oral disclosure, use, exhibition or other means	1	being obvious to a person skilled in the	e art					
priority d	published prior to the international filing date but later than the ate claimed		document member of the same patent	1					
	ctual completion of the international search	Date of ma	ailing of the international sea	rch 078' JUL 2004					
	(07.06.2004)	A mate = ===	2 095						
Mai Con P.O	ailing address of the ISA/US I Stop PCT, Attn: ISA/US nmissioner for Patents . Box 1450 kandria, Virginia 22313-1450		Jofficer B NV G Gibbs Po. (571) 272-0564	2 fr					
	. (703) 305-3230			V					

Form PCT/ISA/210 (second sheet) (July 1998)

U	
Ū	
Ξ	
Z	;
\mathbf{Z}	
5	
ב	
П	•
C	
C	١
Ť	Į
4	

	INTERNATIONAL SE	EARCH REPORT	1			
						
	•					
•						
				·		
				•		
Continuation	on of B. FIELDS SEARCH Medline, EmBase, CancerLit, 1	MED Item 3:				
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer	ence, antibody	•		
search terms	: BubR1, Mad2, Bub3, CENI	P-E, siRNA, RNA-interfer	ence, antibody	·		
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer	ence, antibody			
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer	ence, antibody			
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer	ence, antibody			
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer	ence, antibody			
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer	ence, antibody			
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer	ence, antibody			
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer	ence, antibody			
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer	ence, antibody			
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer	ence, antibody			
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer	ence, antibody		-	
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer	ence, antibody			
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer	ence, antibody			
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer	ence, antibody			
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer				
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer	ence, antibody			
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer				
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer				
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer				
search terms	BubR1, Mad2, Bub3, CENF	P-E, siRNA, RNA-interfer				

PCT/US03/41189